Terms: = Ovarian cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246
451 results:
1. HER2-low and Overexpression in Mucinous ovarian cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
[TBL] [Abstract] [Full Text] [Related]
2. Direct letters to relatives at risk of hereditary cancer-study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study).
Hawranek C; Ehrencrona H; Öfverholm A; Hellquist BN; Rosén A
Trials; 2023 Dec; 24(1):810. PubMed ID: 38105176
[TBL] [Abstract] [Full Text] [Related]
3. Functional and phenotypic consequences of an unusual inversion in msh2.
Pelletier D; Rath A; Sabbaghian N; Pelmus M; Hudon C; Jacob K; Witowski L; Saskin A; Heinen CD; Foulkes WD
Fam Cancer; 2024 Mar; 23(1):1-7. PubMed ID: 37957483
[TBL] [Abstract] [Full Text] [Related]
4. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
5. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract] [Full Text] [Related]
6. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial ovarian cancer.
Wang CW; Lee YC; Lin YJ; Firdi NP; Muzakky H; Liu TC; Lai PJ; Wang CH; Wang YC; Yu MH; Wu CH; Chao TK
Lab Invest; 2023 Nov; 103(11):100247. PubMed ID: 37741509
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract] [Full Text] [Related]
8. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer.
Kim MK; So KA; Chun YK; Kim YH; Lim KT; Lee KH; Kim TJ
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):724-728. PubMed ID: 37679002
[TBL] [Abstract] [Full Text] [Related]
10. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and ovarian cancer.
Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
[TBL] [Abstract] [Full Text] [Related]
11. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
12. Undifferentiated component of dedifferentiated endometrial carcinoma presenting as a "small round cell" malignancy in a mediastinal lymph node, mimicking small cell carcinoma.
Balikani L; Policarpio-Nicolas MLC
Diagn Cytopathol; 2023 Aug; 51(8):519-524. PubMed ID: 37318779
[TBL] [Abstract] [Full Text] [Related]
13. Special features of sarcomas developed in patients with Lynch syndrome: A systematic review.
Poumeaud F; Valentin T; Vande Perre P; Jaffrelot M; Bonnet D; Chibon F; Chevreau C; Selves J; Guimbaud R; Fares N
Crit Rev Oncol Hematol; 2023 Aug; 188():104055. PubMed ID: 37301271
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous ovarian cancer.
Olmez F; Oglak SC; Akgol S; Olmez OF; Bilici A; Akbayir O; Ozkose ZG; Can E; Unal O; Sirinoglu HA
J Coll Physicians Surg Pak; 2023 Jun; 33(6):666-672. PubMed ID: 37300263
[TBL] [Abstract] [Full Text] [Related]
15. DNA Repair Pathway in ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
16. Risk of Syndrome-Associated cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract] [Full Text] [Related]
17. Mismatch repair protein deficiency in endometriosis: Precursor of endometriosis-associated ovarian cancer in women with lynch syndrome.
Yamaguchi M; Mikami Y; Kusunoki M; Yoshimura S; Motohara T; Kondoh E
Taiwan J Obstet Gynecol; 2023 May; 62(3):448-452. PubMed ID: 37188452
[TBL] [Abstract] [Full Text] [Related]
18. High-grade serous ovarian carcinoma with a sertoliform pattern associated with BRCA mutation: a clinicopathological and molecular analysis.
Travaglino A; Santoro A; Arciuolo D; Raffone A; Scaglione G; D'Alessandris N; Valente M; Sfregola S; Fulgione C; Onori ME; Minucci A; Zannoni GF
Virchows Arch; 2023 Dec; 483(6):879-883. PubMed ID: 37166561
[TBL] [Abstract] [Full Text] [Related]
19. Germline drivers of gynecologic carcinosarcomas.
Sia TY; Gordhandas SB; Birsoy O; Kemel Y; Maio A; Salo-Mullen E; Sheehan M; Hensley ML; Rubinstein M; Makker V; Grisham RN; O'Cearbhaill RE; Roche KL; Mueller JJ; Leitao MM; Sonoda Y; Chi DS; Abu-Rustum NR; Berger MF; Ellenson LH; Latham A; Stadler Z; Offit K; Aghajanian C; Weigelt B; Mandelker D; Liu YL
Gynecol Oncol; 2023 Jul; 174():34-41. PubMed ID: 37149903
[TBL] [Abstract] [Full Text] [Related]
20. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract] [Full Text] [Related]
[Next]
